Table 2. Description of the subset of contacts with sexual exposure, and comparison between individuals developing or not mpox despite post-exposure preventive vaccination, according to univariate analysis, Lyon, France, June–August 2022 (n = 53).
| Characteristics | Descriptive analysisa | Simple logistic regression analysisb | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Sexual exposure (n = 53) |
Developed breakthrough mpox (n = 10) |
Did not develop breakthrough mpox (n = 43) |
p-value | OR (95% CI) | p-value | ||||
| Numberc | %c | Numberc | %c | Numberc | %c | ||||
| Demographic characteristics | |||||||||
| Male sexd | 53 | 100 | 10 | NP | 43 | 100 | > 0.9999 | NC | NC |
| Age in yearse | Median (IQR) | 0.4209 | 0.95 (0.86–1.03) | 0.2920 | |||||
| 34 (29–40.5) | 32 (28–35.3) | 34 (29–43) | |||||||
| Information related to immunity or immunisationf | |||||||||
| History of smallpox vaccination | 7 | 13 | 1 | NP | 6 | 14 | > 0.9999 | 0.69 (0.03–4.76) | 0.7407 |
| Immunosuppression | 14 | 26 | 4g | NP | 10h | 23 | 0.4258 | 2.20 (0.48–9.37) | 0.2864 |
| HIV infection | 13 | 25 | 3 | NP | 10 | 23 | 0.6924 | 1.41 (0.27–6.21) | 0.6563 |
| Number of days from exposure to vaccinationi | Median (IQR) | 0.0854 | 0.83 (0.66–1.01) | 0.0811 | |||||
| 9 (4.5–10.0) | 6 (3.0–9.3) | 9 (5.0–11.0) | |||||||
CI: confidence interval; NC: not calculable; NP: not presented due to the small sample size; OR: odds ratio.
a Groups were compared using Fisher’s exact test or Mann–Whitney test, as appropriate.
b OR (and their 95% CI) were estimated separately using simple logistic regression analysis.
c Unless specified otherwise in certain cells of the table.
d Information on sex was collected as a binary variable. ORs for male participants were not calculable.
e Age was handled as a continuous variable and OR represents the change in odds by each one-year increase.
f References for the ORs in this section were the absence of the characteristic in question (i.e. no smallpox immunisation, no immunosuppression, and no HIV).
g Including three people living with HIV and one person receiving a TNFα inhibitor.
h Including 10 people living with HIV (1/10 with concomitant haematological malignancy).
I Time from exposure to vaccination was handled as a continuous variable and OR represents the change in odds by each one-day increase.
p values < 0.2 are in bold type.